Manage cardiovascular risk in patients with type 2 diabetes by using agents with proven cardiovascular benefits
AbstractAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). Not only is T2D a risk factor for ASCVD, common comorbid conditions, such as dyslipidaemia and hypertension, are also risk factors for ASCVD. Controlling these risk factors with agents with proven cardiovascular benefits (e.g. metformin, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 receptor inhibitors, statins, ACE inhibitors and angiotensin receptor blockers) provides considerable clinical benefits.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Heart | Hypertension | Metformin | Sodium | Statin Therapy